MBX Biosciences is trading 6.3% down at $57.22 as the stock continues to consolidate following a massive multi-month rally and recent profit-taking.
- Recent coverage highlights insider selling and valuation concerns following the stock's sharp run-up, with no fresh company-specific news or regulatory events reported today.
- The broader biotech sector is also trading lower, suggesting the decline is part of a sentiment-driven pullback across the industry.